Expression of MHC I and NK ligands on human CD133+ glioma cells: possible targets of immunotherapy.
about
Methodology for Anti-Gene Anti-IGF-I Therapy of Malignant TumoursFocus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human gliomaTumorsphere as an effective in vitro platform for screening anti-cancer stem cell drugsImmune responses to human cancer stem-like cells/cancer-initiating cellsEmerging therapeutic biomarkers in endometrial cancerUsing LongSAGE to Detect Biomarkers of Cervical Cancer Potentially Amenable to Optical Contrast Agent Labelling.Immunocompetent murine models for the study of glioblastoma immunotherapyImmunobiological characterization of cancer stem cells isolated from glioblastoma patients.Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapy.Stem cells for ischemic brain injury: a critical review.Myxoma virus infection promotes NK lysis of malignant gliomas in vitro and in vivo.Natural killer-cell differentiation by myeloid progenitorsDendritic cells loaded with pancreatic Cancer Stem Cells (CSCs) lysates induce antitumor immune killing effect in vitroDynamics of Circulating γδ T Cell Activity in an Immunocompetent Mouse Model of High-Grade Glioma.Deciphering the Multifaceted Relationship between Oncolytic Viruses and Natural Killer CellsConcise Review: Targeting Cancer Stem Cells Using Immunologic ApproachesVSIG4 is highly expressed and correlated with poor prognosis of high-grade glioma patients.Glioma Stemlike Cells Enhance the Killing of Glioma Differentiated Cells by Cytotoxic Lymphocytes.Immune phenotypes predict survival in patients with glioblastoma multiforme.Polarized cell migration induces cancer type-specific CD133/integrin/Src/Akt/GSK3β/β-catenin signaling required for maintenance of cancer stem cell properties.Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T CellsNK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors.Hitting Them Where They Live: Targeting the Glioblastoma Perivascular Stem Cell Niche.Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma.Highlights of the First International "Immunotherapy in Pediatric Oncology: Progress and Challenges" Meeting.Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells.Tumor initiating cells in malignant gliomas: biology and implications for therapy.Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells.Targeting CD133 antigen in cancer.NK cell-based autologous immune enhancement therapy (AIET) for cancer.Targeting tissue factor as a novel therapeutic oncotarget for eradication of cancer stem cells isolated from tumor cell lines, tumor xenografts and patients of breast, lung and ovarian cancer.Immunotherapy targeting colon cancer stem cells.Cellular immunotherapy for high-grade glioma.Immunotherapy of prostate cancer: should we be targeting stem cells and EMT?Cancer immunoediting in malignant glioma.Achieving graft-versus-tumor effect in brain tumor patients: from autologous progenitor cell transplant to active immunotherapy.Cancer stem cell markers: what is their diagnostic value?ER-mitochondria contacts control surface glycan expression and sensitivity to killer lymphocytes in glioma stem-like cells.Improving vaccine efficacy against malignant gliomaId1 and NF-κB promote the generation of CD133+ and BMI-1+ keratinocytes and the growth of xenograft tumors in mice.
P2860
Q21284986-39FF346A-BC81-45B4-B594-7A6ADB16090BQ24615166-691EA1DB-0937-48AE-B9AF-79992A9380FCQ26777335-67757CA4-B038-4ACC-BE7A-A205A1A7294EQ26781794-E8D02BD6-0B34-48FE-8C7D-A3AFBB28F8ABQ26865904-A7A84D89-64CD-417A-B872-F9805122D0D6Q33491567-E9BB7679-B1C7-40A3-B478-6CBE81A177CAQ33574853-8DAED0D4-D2E7-43C8-A243-280B11E6C507Q33740546-81506D39-E141-4514-BCDD-6A380A5498EBQ33789543-9A17580B-1C77-48CE-B363-BA7F33133C30Q33957236-2CF18433-BA1E-4EA8-B115-3CD358274BF6Q34770719-532F1063-8707-4688-B06F-9A7975E74E80Q34773999-C877D4B9-7E60-4BA2-A72C-6340979A477AQ35529398-13968BCD-A053-4E97-B651-2061AFA36739Q35587132-868AD7BC-1B16-4681-9679-A8CDEC5E70F8Q35687743-1FAEE3E5-6C7B-4C80-BD49-197E6E6A877CQ35772708-359F8C6D-622B-473D-B047-625C580B5917Q35941343-EF7BF70F-A37F-43F7-B435-DABB682BB6C1Q35988225-67BCCE9E-94CA-4764-821F-F50F311FA246Q36120388-FE9FD5E4-5761-4191-B4DF-D1DDAEE369B9Q36545955-050B7FED-0B7F-4648-8D37-E2FD9AE4874FQ36626774-8BCA4634-BC89-4ED3-8ACA-09F52389B6FCQ36890816-10F3F084-F791-47D9-BF41-501C30D404BAQ36916624-D07D52F3-B22E-4570-B1DB-D9F5D6C1F435Q37126620-8CB22D1D-69B8-4872-9674-1C841D80BF3EQ37271276-365C4980-7FD2-4919-8312-31C4455D6F9FQ37358942-D1C15648-41C7-4F0D-93A1-FC6AD89C9A37Q37384328-1B1E8636-2DE6-4731-B9E0-8ACF9A7ADAC0Q37461075-629FFB07-2C2A-45FD-B1F0-C9FE63F87EE2Q37521082-0859890A-B282-4C6C-8BFF-5799C66F3046Q37536206-FBEF3ECF-8B9D-4165-BFAD-1E84A9B381CCQ37702117-44808780-619B-47FF-B0C5-B40752A328C3Q37822747-3211266A-8D31-4B3C-9F5F-8E58CDE28AB6Q37851972-3855DFBF-B4E7-4D05-8101-7601E241ECEBQ37891875-BAFD12E8-F705-4BA6-A7A4-FA84740C0A42Q37986999-C756F818-3AB9-4E31-AC0A-94A9577C6719Q38063583-5E3DBE4B-3BA7-47C2-B754-8F70D21CE87FQ38089898-257A4B23-7946-4349-9A29-E41E1B6715E7Q38712677-A8657EA0-3EF9-4F08-B3DE-6FBE329AB614Q38953024-0F64BB87-E5ED-4605-823E-F6DB9F3B8DEEQ39020692-89BD36D2-A038-4B62-A1BE-3C7BD8170DD0
P2860
Expression of MHC I and NK ligands on human CD133+ glioma cells: possible targets of immunotherapy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Expression of MHC I and NK lig ...... ible targets of immunotherapy.
@en
Expression of MHC I and NK lig ...... ible targets of immunotherapy.
@nl
type
label
Expression of MHC I and NK lig ...... ible targets of immunotherapy.
@en
Expression of MHC I and NK lig ...... ible targets of immunotherapy.
@nl
prefLabel
Expression of MHC I and NK lig ...... ible targets of immunotherapy.
@en
Expression of MHC I and NK lig ...... ible targets of immunotherapy.
@nl
P2093
P1476
Expression of MHC I and NK lig ...... ible targets of immunotherapy.
@en
P2093
John R Ohlfest
Katya Ericson
Steve Wiesner
Walter A Hall
Walter C Low
P2888
P304
P356
10.1007/S11060-006-9265-3
P577
2006-11-01T00:00:00Z